South Korea
· Delayed Price · Currency is KRW Optipharm.CO.,LTD Statistics
Total Valuation
Optipharm.CO.,LTD has a market cap or net worth of KRW 68.80 billion. The enterprise value is 64.90 billion.
| Market Cap | 68.80B |
| Enterprise Value | 64.90B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Optipharm.CO.,LTD has 14.67 million shares outstanding. The number of shares has decreased by -0.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 14.67M |
| Shares Change (YoY) | -0.17% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.96% |
| Owned by Institutions (%) | n/a |
| Float | 8.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.60 |
| PB Ratio | 2.94 |
| P/TBV Ratio | 2.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -28.60 |
| EV / Sales | 3.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -41.93 |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.48.
| Current Ratio | 1.64 |
| Quick Ratio | 1.37 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | -7.21 |
| Interest Coverage | -4.44 |
Financial Efficiency
Return on equity (ROE) is -9.05% and return on invested capital (ROIC) is -4.16%.
| Return on Equity (ROE) | -9.05% |
| Return on Assets (ROA) | -3.68% |
| Return on Capital (ROIC) | -4.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.47 |
| Inventory Turnover | 11.32 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.40% |
| 50-Day Moving Average | 4,922.60 |
| 200-Day Moving Average | 5,944.35 |
| Relative Strength Index (RSI) | 43.61 |
| Average Volume (20 Days) | 7,521 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Optipharm.CO.,LTD had revenue of KRW 19.09 billion and -2.27 billion in losses. Loss per share was -155.00.
| Revenue | 19.09B |
| Gross Profit | 4.64B |
| Operating Income | -2.38B |
| Pretax Income | -2.27B |
| Net Income | -2.27B |
| EBITDA | -799.58M |
| EBIT | -2.38B |
| Loss Per Share | -155.00 |
Balance Sheet
The company has 15.07 billion in cash and 11.17 billion in debt, giving a net cash position of 3.91 billion or 266.21 per share.
| Cash & Cash Equivalents | 15.07B |
| Total Debt | 11.17B |
| Net Cash | 3.91B |
| Net Cash Per Share | 266.21 |
| Equity (Book Value) | 23.43B |
| Book Value Per Share | 1,597.01 |
| Working Capital | 7.92B |
Cash Flow
In the last 12 months, operating cash flow was -349.43 million and capital expenditures -1.20 billion, giving a free cash flow of -1.55 billion.
| Operating Cash Flow | -349.43M |
| Capital Expenditures | -1.20B |
| Free Cash Flow | -1.55B |
| FCF Per Share | -105.51 |
Margins
Gross margin is 24.32%, with operating and profit margins of -12.45% and -11.89%.
| Gross Margin | 24.32% |
| Operating Margin | -12.45% |
| Pretax Margin | -11.89% |
| Profit Margin | -11.89% |
| EBITDA Margin | -4.19% |
| EBIT Margin | -12.45% |
| FCF Margin | n/a |
Dividends & Yields
Optipharm.CO.,LTD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.17% |
| Shareholder Yield | 0.17% |
| Earnings Yield | -3.30% |
| FCF Yield | -2.25% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Optipharm.CO.,LTD has an Altman Z-Score of 3.23.
| Altman Z-Score | 3.23 |
| Piotroski F-Score | n/a |